Drug approvals, treatment advances, trial results and research breakthroughs.
1 item
CARsgen's satricabtagene autoleucel (satri-cel) is under priority review by China's NMPA for advanced gastric and gastroesophageal junction cancer, and it could be the world's first CAR-T therapy approved for a solid tumor. Here's what the data shows and what it means for patients.
